Safety/Tolerability Study With AZD1236 in Chronic Obstructive Pulmonary Disease (COPD) Patients
NCT ID: NCT00758459
Last Updated: 2011-08-19
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
74 participants
INTERVENTIONAL
2008-09-30
2009-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Phase IIa Study Assessing the Effects of AZD1236 on Biomarkers in Chronic Obstructive Pulmonary Disease (COPD) Patients
NCT00758706
A 4 Week Study to Investigate the Safety and Tolerability of AZD5069 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
NCT01233232
AZD2423 Safety and Tolerability Study in Patients With Moderate and Severe Chronic Obstructive Pulmonary Disease(COPD)
NCT01215279
Study to Assess the Efficacy and Safety of AZD1981 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
NCT00690482
Tolerability/Safety and Efficacy of Inhaled AZD4818 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
NCT00629239
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
AZD1236
oral tablet, 75 mg, twice daily during 6 weeks
2
Placebo
Dosing to match AZD1236
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AZD1236
oral tablet, 75 mg, twice daily during 6 weeks
Placebo
Dosing to match AZD1236
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Men or postmenopausal women
* Spirometry values indicating reduced lung function
* Smoking history equivalent to using 20 cigarettes a day for 10 years
Exclusion Criteria
* Requirement for regular oxygen therapy
* Use of oral or parenteral glucocorticosteroids within 30 days prior to the study
40 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
AstraZeneca Pharmaceuticals
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Helgo Magnussen, MD, Professor
Role: PRINCIPAL_INVESTIGATOR
Pulmonary research institute at Hospital Grosshansdorf, Wöhrendamm, Grosshansdorf Germany
Andrew Lockton, MD
Role: STUDY_DIRECTOR
AstraZeneca R&D Charnwood
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Rousse, , Bulgaria
Research Site
Sofia, , Bulgaria
Research Site
Helsinki, , Finland
Research Site
Oulu, , Finland
Research Site
Preitilä, , Finland
Research Site
Berlin, , Germany
Research Site
Grobhansdorf, , Germany
Research Site
Győr, , Hungary
Research Site
Komló, , Hungary
Research Site
Pécs, , Hungary
Research Site
Vásárosnamény, , Hungary
Research Site
Bojnice, , Slovakia
Research Site
Liptovský Hrádok, , Slovakia
Research Site
Žilina, , Slovakia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D4260C00003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.